P3 Health Partners Inc (PIII)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Last updated: Nov 16, 2026 at 4:00 PM ET
P3 Health Partners Inc (PIII) Earnings: Report Dates and Results
P3 Health Partners (PIII) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, P3 Health Partners reported EPS of $0.07, above the -$7.40 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PIII has an expected report date of Mar 24, 2027.
PIII Earnings Call
The latest PIII earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 21 quarters below that had an estimate, PIII beat 10, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $396.34M, up 14.8% from $345.25M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.07 | -$7.40 | -$7.40 - -$7.40 | +100.95% | Beat | N/A | 1 | 0 up, 1 down | Nov 9, 2026 | $396.34M |
| Jun 30, 2026 | -$0.63 | -$1.89 | -$2.10 - -$1.69 | +66.67% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2026 | $386.38M |
| Mar 31, 2026 | $0.32 | -$3.50 | -$3.73 - -$3.28 | +109.14% | Beat | N/A | 2 | 1 up, 0 down | May 14, 2026 | $386.39M |
| Dec 31, 2025 | -$23.02 | -$9.47 | -$9.85 - -$9.08 | -143.21% | Miss | N/A | 2 | 0 up, 2 down | Mar 26, 2026 | $384.81M |
| Sep 30, 2025 | -$9.67 | -$6.04 | -$7.03 - -$4.31 | -60.10% | Miss | N/A | 3 | 0 up, 2 down | Nov 14, 2025 | $345.25M |
| Jun 30, 2025 | -$6.23 | -$4.30 | N/A | -44.88% | Miss | N/A | N/A | 0 up, 0 down | Aug 14, 2025 | $355.79M |
| Mar 31, 2025 | -$6.28 | $5.00 | N/A | -225.60% | Miss | N/A | N/A | 0 up, 0 down | May 15, 2025 | $373.23M |
| Dec 31, 2024 | -$0.36 | -$0.11 | N/A | -227.27% | Miss | N/A | N/A | 0 up, 0 down | Mar 27, 2025 | $329.31M |
| Sep 30, 2024 | -$14.50 | -$1.87 | -$3.00 - -$1.50 | -675.40% | Miss | N/A | 4 | 0 up, 0 down | Nov 12, 2024 | $362.12M |
| Jun 30, 2024 | -$4.50 | -$4.83 | -$5.50 - $4.50 | +6.83% | Beat | N/A | 4 | 1 up, 0 down | Aug 7, 2024 | $379.16M |
| Mar 31, 2024 | -$8.00 | -$6.37 | -$7.50 - -$4.00 | -25.59% | Miss | N/A | 3 | 0 up, 0 down | May 8, 2024 | $388.49M |
| Dec 31, 2023 | -$0.22 | -$0.11 | -$0.19 - -$0.05 | -100.00% | Miss | -100.0% | 4 | 0 up, 0 down | Mar 28, 2024 | $346.86M |
| Sep 30, 2023 | -$6.00 | -$11.00 | -$23.50 - -$3.00 | +45.45% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2023 | $288.35M |
| Jun 30, 2023 | -$4.50 | -$6.50 | -$12.00 - -$3.50 | +30.77% | Beat | N/A | 3 | 0 up, 0 down | Aug 7, 2023 | $329.09M |
| Mar 31, 2023 | -$0.22 | -$0.67 | -$1.26 - -$0.22 | +67.16% | Beat | N/A | 2 | 0 up, 0 down | May 10, 2023 | $302.08M |
| Dec 31, 2022 | $444.11 | -$45.50 | -$78.00 - -$13.00 | N/A | N/A | N/A | 2 | 0 up, 0 down | Mar 31, 2023 | $258.21M |
| Sep 30, 2022 | -$13.50 | -$9.00 | N/A | -50.00% | Miss | N/A | N/A | N/A | Nov 14, 2022 | $248.26M |
| Jun 30, 2022 | -$0.21 | -$0.23 | N/A | +8.70% | Beat | N/A | N/A | N/A | Aug 31, 2022 | $269.45M |
| Mar 31, 2022 | -$0.36 | -$0.36 | N/A | 0.00% | In line | -400.0% | 3 | 0 up, 0 down | Apr 25, 2022 | $273.54M |
| Dec 31, 2021 | -$0.05 | -$0.24 | -$0.36 - -$0.12 | +79.17% | Beat | N/A | 3 | 0 up, 0 down | Jan 7, 2022 | N/A |
| Sep 30, 2021 | -$0.13 | -$0.45 | N/A | +71.11% | Beat | N/A | N/A | N/A | Dec 9, 2021 | $156.19M |
| Jun 30, 2021 | -$0.33 | -$0.33 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 19, 2021 | $144.59M |
| Mar 31, 2021 | $0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 6, 2021 | $151.30M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$45.20, after -$27.36 the year before. It was -$0.39 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$45.20 | N/A |
| Dec 31, 2024 | -$27.36 | N/A |
| Dec 31, 2023 | -$10.94 | -102.5% |
| Dec 31, 2022 | $430.04 | N/A |
| Dec 31, 2021 | -$0.39 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,297 | 7 | |
| 2026Q2 | Jun 30, 2026 | 4,232 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,641 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,926 | 8 | |
| 2025Q2 | Jun 30, 2025 | 5,972 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,478 | 8 | |
| 2024Q3 | Sep 30, 2024 | 5,289 | 9 | |
| 2024Q2 | Jun 30, 2024 | 5,721 | 11 |
2026Q3 Earnings Call
Opening remarks
William Hoover Head of Investor Relations Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under the U.S. Federal Securities Laws, including statements regarding our financial outlook and long-term target. These forward-looking statements are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise these forward-looking statements. We will refer to certain non-GAAP financial measures on this call, including adjusted operating expense, Adjusted EBITDA, Adjusted EBITDA per member per month, normalized Adjusted EBITDA, medical margin, medical margin per member per month, and cash flow. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, the measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures. For example, other companies may calculate similarly titled non-GAAP financial measures differently. Please refer to the appendix of our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures. Information presented on this call is contained in the press release that we issued today and in our SEC filings, which may be accessed from the Investor page of the P3 Health Partners website. I will now turn the call over to Aric Coffman, CEO of P3 Health Partners.
Aric Coffman CEO Good afternoon, and thank you for joining us today to discuss our third-quarter results. It has been two and a half years since I began leading P3, and the changes we have made across the business continue to build on one another. Our third-quarter results reflect that work, with $21 million of Adjusted EBITDA, bringing our year-to-date Adjusted EBITDA to $101 million. As a result, we are raising the low end of our full-year Adjusted EBITDA guidance to $90 million, increasing the midpoint to $100 million. Our focus now is on building upon the durable foundation we have created. We have four areas of focus: medical cost management, quality and burden-of-illness documentation, disciplined growth, and refining our operations through people, process, and technology.
Frequently Asked Questions About PIII
When is P3 Health Partners's next earnings date?
P3 Health Partners's next earnings report is expected for Mar 24, 2027.
Did PIII beat earnings estimates last quarter?
Yes. P3 Health Partners reported EPS of $0.07 for the quarter ended Sep 30, 2026, above the -$7.40 estimate, a 100.95% surprise.
What EPS do analysts expect from PIII next quarter?
The consensus EPS estimate for P3 Health Partners for the quarter ending Dec 31, 2026 is -$5.73 from 4 analysts, with estimates from -$6.90 to -$4.41.
How often does PIII beat earnings estimates?
P3 Health Partners beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -53.04%.
PIII pages: Overview, Earnings, Forecast, Financials, Competitors